Speciality Medicines Limited has announced a major business development with the securing of an international order valued at USD 2 million, approximately ₹18.8 crores. The pharmaceutical company disclosed this significant commercial arrangement in a regulatory filing dated 23/04/2026.

Order Details and Commercial Arrangement

The company has finalized a commercial partnership with an international entity that specializes in importing and distributing pharmaceutical finished products. Under this arrangement, the international partner will handle the distribution, marketing, and sales of Speciality Medicines Limited's products.

Strategic Impact on Business Operations

The management expects this arrangement to deliver significant benefits to the company's operational framework. The partnership is anticipated to substantially enhance Speciality Medicines Limited's distribution network while providing improved revenue visibility for future periods.

The international collaboration represents a strategic expansion of the company's market reach through an established distribution partner with expertise in pharmaceutical finished products. This approach allows the company to leverage existing distribution infrastructure and market knowledge of the international entity.

Transaction Compliance and Governance

Speciality Medicines Limited has confirmed full compliance with regulatory requirements regarding this commercial arrangement. The company explicitly stated that none of its promoters, promoter group members, or group companies have any financial interest in this order or contract.

Additionally, the transaction has been classified as not falling under related party transaction regulations, ensuring transparency and adherence to corporate governance standards. This classification provides clarity on the independent nature of the commercial relationship with the international distributor.

Company Background

Speciality Medicines Limited, formerly known as Speciality Medicines Private Limited, operates as an exporter and trader of specialty pharmaceutical products. The company maintains its corporate office in Mumbai and registered office in Ahmedabad, with operations focused on pharmaceutical finished products for both domestic and international markets. The announcement was signed by Parthkumar Goyani, Chairman and Managing Director.

Speciality Medicines Limited has submitted its quarterly compliance certificate to BSE Limited, fulfilling regulatory requirements under SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended March 31, 2026.

Regulatory Compliance Filing

The company submitted the confirmation certificate under Regulation 74(5) of SEBI regulations on April 15, 2026. The certificate was signed by Parthkumar Goyani, Chairman and Managing Director (DIN: 07885789), and submitted to BSE Limited at P.J. Towers, Dalal Street, Fort, Mumbai.

RTA Confirmation Certificate

Skyline Financial Services Private Limited, serving as the company's Registrar and Share Transfer Agent, issued the confirmation certificate dated April 03, 2026. The certificate confirms that no physical share certificates were received for dematerialization of equity shares during the quarter ended March 31, 2026.

The RTA certificate was signed by Parveen Sharma, Authorised Signatory of Skyline Financial Services Private Limited, and bears the official company stamp from New Delhi.

Company Information

Speciality Medicines Limited (formerly known as Speciality Medicines Private Limited) operates as an exporter and trader of specialty medicines. The company details include:

This quarterly filing represents standard regulatory compliance, ensuring transparency in the company's share transfer and dematerialization processes as mandated by SEBI regulations for listed entities.